Sagimet down as Chinese partner posts late-stage trial data for acne therapy
Source: SeekingAlpha
2026-01-29 08:17:13 ET
More on Sagimet Biosciences, Ascletis Pharma Inc.
- Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market
- Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
- Sagimet rises as licensing deal with Teva unit targets Madrigal drug
- Seeking Alpha’s Quant Rating on Sagimet Biosciences
- Historical earnings data for Sagimet Biosciences
Read the full article on Seeking Alpha
For further details see:
Sagimet down as Chinese partner posts late-stage trial data for acne therapy
Sagimet Biosciences Inc.
NASDAQ: SGMT
SGMT Trading
0.27% G/L:
$5.445 Last:
117,276 Volume:
$5.37 Open:
SGMT Latest News
February 05, 2026 07:00:00 am
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
February 02, 2026 07:00:00 am
Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
January 27, 2026 03:00:00 am
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
January 08, 2026 07:00:00 am
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
SGMT Stock Data
$183,421,818
25,724,585
0.29%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
San Mateo
